I am interested in cancer and how it interacts with our immune system. It is my belief that to push oncology forward we must adopt new strategies. Instead of relying solely on surgery, radiation or chemotherapy, cellular therapies – where we utilize the immune system – are poised to transform the way we treat and manage cancer.
Currently I am interested in three aspects of tumor-immunology: a) factors that inhibit T cell migration and movement in tumours, b) exploration of genes that increase cytotoxicity of T-cells and c) defining surface markers on cancer cells suitable as targets.
2019: Barnkob MB, Michaels YS, André V, Macklin PS, Gileadi U, Valvo S, Rei M, Kulicke C, Chen JL, Jain V, Woodcock V, Colin-York H, Hadjinicolaou AV, Kong Y, Mayya V, Bull JA, Rijal P, Pugh CW, Townsend AR, Olsen LR, Fritzsche M, Fulga TA, Dustin ML, Jones EY, Cerundolo V. Semaphorin 3A induces cytoskeletal paralysis in tumor-specific CD8+ T cells. December, 2019. [Preprint].
2019: Michaels YS, Barnkob MB, Barbosa H, Baeumler TA, Thompson MK, Andre V, Colin-York H, Fritzsche M, Gileadi U, Sheppard HM, Knapp DJHF, Milne TA, Cerundolo V, Fulga TA. Precise tuning of gene expression levels in mammalian cells. Nature Communications, February, 2019. [Preprint]. [Link].
2018: Funck T, Barnkob MB, Holm N, Ohm-Laursen L, Mehlum CS, Möller S, Barington T. Analysis of human immunoglobulin VDJ and DJ rearrangements shows N region synthesis by concatenation of cytosine-rich strands preferentially originating from trimmed germline gene segments. January, 2018. [Preprint]. [Link].
2014: Olsen LR*, Campos B*, Barnkob MS*, Winther O, Brusic V, Andersen MH. Bioinformatics for cancer immunotherapy target discovery. Cancer Immunology, Immunotherapy, October 2014. Review. [Link].
2013: Bak SP*, Barnkob MS*, Wittrup KD, Chen J. Immunoediting of Antigen Expressing Cells after Treatment with Prostate Tumor Specific T Cells. Cancer Immunology Research, September 2013. [Link]
2012: Bak SP, Barnkob MS, Bai A, Higham EM, Wittrup KD, Chen J. Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T Cells. Journal of Immunology, August 2012. [Link]
*Shared first authorship.